Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
Date:3/24/2011

REDWOOD CITY, Calif., March 24, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute or breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2010.

Net loss for the fourth quarter of 2010 was $3.5 million, or $5.23 per common share, compared with a net loss of $3.7 million, or $6.05 per common share, for the fourth quarter of 2009. Net loss for the year ended December 31, 2010 was $14.3 million, or $21.84 per common share, compared to a net loss of $20.1 million, or $34.93 per common share, for the year ended December 31, 2009.

Research and development expenses for the twelve and three months ended December 31, 2010 totaled $8.2 million and $1.9 million, compared to $15.5 million and $2.3 million for the twelve and three months ended December 31, 2009. General and administrative expenses were $4.0 million and $1.0 million for the year and quarter ended December 31, 2010, compared to $3.5 million and $1.0 million for the year and quarter ended December 31, 2009.

As of December 31, 2010, AcelRx had cash, cash equivalents and short-term investments of $3.7 million, compared to $12.5 million as of December 31, 2009. On February 16, 2011, AcelRx closed its initial public offering of 8.0 million shares of common stock resulting in net proceeds to AcelRx of $35.6 million.  We intend to utilize these funds primarily for advancement of our lead program, our hospital-based, patient-controlled analgesia (PCA) product, the Sufentanil NanoTab PCA System (ARX-01).

"We are pleased with our progress towards initiating the Phase 3 program for ARX-01 in acute post-operative pain," said Richard King, President and Chief Executive Officer of AcelRx. "We anticipate
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
3. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
4. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
7. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
8. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
9. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
10. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
(Date:1/22/2015)... UPI ), a medical device company that ... voiding dysfunctions, today reported financial results for the fiscal ... revenue for the Company,s Urgent ®  PC Neuromodulation System ... record, as compared to $3.9 million in the third ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... SAN FRANCISCO, Calif., May 10, 2011 Janssen ... Alzheimer,s Immunotherapy Program, Pfizer Inc., is pleased to ... health organization in Alzheimer,s care, support and research, ... Summits Climb for Alzheimer,s: Memories are Everything ...
... Vista Partners announced today that it ... (AMEX: HBP, TSX: HBP) ("the Company") with a twelve ... at Vista Partners stated, "The Company is developing products ... and most advanced, Interferon alpha-2b, is a potent immuno-modulatory ...
Cached Medicine Technology:Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 2Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 3Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 4Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20 2
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... Medical College of Georgia has again been designated by ... Oncology Program. , The renewal, which comes with a ... latest cancer treatment and prevention strategies for all cancer ... the MCG section of Hematology/Oncology and principal investigator on ...
... boosted the odds by 67%, study found , THURSDAY, Dec. ... an abortion are much more likely than women who haven,t ... new research shows. , A team at Virginia Commonwealth University ... in the United States Collaborative Perinatal Project. , About 40 ...
... -- A Las Vegas business and Oak Ridge National Laboratory ... dehydration or congestive heart failure. , The task for ORNL ... improve and miniaturize Noninvasive Medical Technologies ZOE, a medical device ... is of great importance to members of the military and ...
... for runners who struggle to increase their pace, cyclists who ... their strokes. Researchers from the University of Exeter and Kansas ... our muscles when we push ourselves during exercise. , ... as the critical power. This level can increase as we ...
... years after patients were given Nobel Direct dental implants, the ... follow-up by researchers at the Sahlgrenska Academy in Sweden shows ... , Nobel Direct was launched in 2004 by Nobel Biocare ... could be screwed directly into the jawbone without having to ...
Cached Medicine News:Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:MCG receives second-time designation from National Cancer Institute 2Health News:MCG receives second-time designation from National Cancer Institute 3Health News:Prior Miscarriage Raises Risk for Low-Birthweight Infant 2Health News:Nevada company, ORNL develop potential lifesaver 2Health News:Why exertion leads to exhaustion 2Health News:Gloomy forecast for Nobel Direct after 3 years 2
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA test for Clostridium difficile antigen that ... sensitivity. That means the laboratory can quickly, ... negatives - which can represent up to ... the organism - and be sure that ...
Medicine Products: